GenSight Biologics reports data from REVERSE Phase III trial on LHON

GenSight Biologics has reported further results from its REVERSE Phase III clinical trial for the treatment of Leber hereditary optic neuropathy (LHON).

The trial analyses the safety and efficacy of a single intravitreal injection of GS010 (rAAV2/2-ND4) in 37 subjects suffering with visual loss due to 11778-ND4 LHON.

At 72 weeks, the study observed an improvement from baseline in mean visual acuity in eyes treated with GS010. Concomitant contralateral improvement was found to be of +12 letters (-0.246 LogMAR) in sham-treated eyes.

These results extend the positive trend reported at 48 weeks, indicating a sustained outcome for the trial patients.

An improvement was also seen in contrast sensitivity, as per the Pelli-Robson low-contrast testing.

In week 72, GS010-treated eyes gained on average +0.21 LogCS versus baseline, while sham-treated eyes had seen +0.15 LogCS.

“We’re seeing visual function continue to improve one and a half years after eyes are treated with GS010.”

The proportion of treated eyes that experienced a clinical improvement of at least 0.3 LogCS (45.9%) was statistically higher than that of the sham-treated eyes (24.3%).

The outcome for visual function was also complemented by evidence that GS010 was engaging its anatomic targets, the ganglion cells.

High-resolution Spectral-Domain Optical Coherence Tomography (SD-OCT) demonstrated preservation of the retina anatomy at 72 weeks.

The ganglion cell layer macular volume was preserved in treated eyes, while it deteriorated in sham-treated eyes from baseline.

Drug-treated eyes also indicated a reduced loss in thickness of the temporal quadrant of the retinal fiber layer of -1.6µm, as against a loss of -3.6µm in sham-treated eyes.

GenSight co-founder and CEO Bernard Gilly said: “We’re seeing visual function continue to improve one and a half years after eyes are treated with GS010, and at the same time, objective tests continue to establish neuroprotection of the retina in treated eyes. This is, beyond any doubt, a great benefit for patients and their families.”

“These results strengthen our determination to work with regulatory agencies to bring GS010 to market within our defined timelines.”

Free Whitepaper

Revolutionising chromatography and clarification in biopharma production

Biopharma companies are under constant pressure to improve productivity, maintain product purity, and cut costs. Yet this is far from straightforward. Process intensification is desired, but there are barriers to making processes more efficient. Chromatography and clarification play vital parts in biopharma manufacturing, yet there is room for improvement in processes to eliminate inefficiencies and increase yield. Single-stage clarification technologies, such as 3M™ Harvest RC Chromatographic Clarifier, could play a vital role in this journey, by simplifying what would otherwise be a time-consuming and complex clarification train. This document delves into the history of chromatography and clarification, addresses problems, proposes solutions, and offers a glimpse into what the future may look like after a revolution in biopharma production processing. Download to learn more.

By 3M

The information you provide are used by 3M Company and its group companies, in accordance with 3M Global Privacy Policy as shown at 3M.com/privacy, for the purpose of (i) following up with you via email or telephone on any event sponsored / co-organized / participated by 3M, your questions, interests or requests; (ii) making materials available to you; and (iii) inviting you to future events; and (iv) based on your consent, sending you newsletters, advertisements, surveys and information about promotions and offers of 3M Company and its group companies via email. Please use the Intake form to object. EMEA residents: please read 3M privacy notice, opt in language & exact information on 3M data controller relevant to your location here

By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.